Force majeure clauses in biotech supply contracts

Introduction

Force majeure clauses in biotechnology supply contracts are contractual provisions that address extraordinary events beyond the reasonable control of contracting parties that prevent or significantly delay the performance of contractual obligations. These clauses are particularly important in biotechnology because supply chains may depend on specialised biological materials, laboratory equipment, vaccines, pharmaceutical ingredients, genetically engineered products, and temperature-controlled transportation systems.

Unexpected events such as pandemics, natural disasters, government restrictions, international trade disruptions, and transportation failures may interrupt the supply of essential biotechnology products.

Force majeure clauses help allocate financial and legal risks between manufacturers, suppliers, distributors, and research institutions. They also establish procedures for notifying affected parties, mitigating losses, suspending obligations, and terminating contracts when performance becomes impossible or commercially impracticable under the agreed terms.

Meaning and objectives of force majeure

Force majeure refers to extraordinary circumstances that prevent a party from fulfilling contractual obligations despite taking reasonable precautions.

The principal objectives include:

Protecting parties against liability for qualifying unforeseen events.

Establishing procedures for handling supply-chain disruptions.

Defining temporary suspension of contractual obligations.

Allocating financial risks arising from unexpected events.

Providing mechanisms for contract extension or termination.

Maintaining continuity of essential biotechnology supplies.

A force majeure clause does not automatically excuse every delay or financial difficulty. Its application depends on the contractual wording, the nature of the event, and its actual effect on performance.

Legal framework in India

1. Indian Contract Act, 1872

The Indian Contract Act provides the principal legal framework for force majeure disputes.

Important provisions include:

Section 32: Deals with contingent contracts and becomes relevant when contractual performance depends on the occurrence or non-occurrence of a specified event.

Section 56: Addresses agreements to do impossible acts and contracts that become impossible or unlawful after formation.

Where a contract contains an express force majeure clause, the parties' rights are generally examined under Section 32. Where the contract does not provide for the relevant contingency, Section 56 may become applicable.

2. Sale of Goods Act, 1930

The Act governs contracts involving the sale of goods, including relevant biotechnology products. Its provisions concerning delivery, transfer of ownership, and contractual obligations may become important when force majeure affects the supply of biological materials or pharmaceutical products.

3. Specific Relief Act, 1963

The Act provides remedies relating to contractual performance and other civil relief. Its provisions may become relevant where disputes arise concerning the enforcement or termination of biotechnology supply contracts.

Common force majeure events in biotechnology supply contracts

1. Pandemics and public health emergencies

Disease outbreaks may disrupt manufacturing operations, laboratory activities, transportation, and international distribution of vaccines, biological samples, and pharmaceutical ingredients.

2. Natural disasters

Floods, earthquakes, cyclones, and other natural disasters may damage manufacturing facilities, laboratories, storage facilities, or transportation infrastructure.

3. Government restrictions

Export prohibitions, import restrictions, emergency regulations, and other government measures may prevent the movement of biotechnology products across borders.

4. Transportation and logistics disruptions

Biotechnology products may require specialised temperature-controlled transportation. Unexpected interruptions in refrigerated transportation or international shipping may affect product quality and contractual delivery obligations.

5. Industrial accidents

Major fires, explosions, and unexpected facility damage may interrupt production, provided the relevant event satisfies the contractual force majeure requirements.

Essential elements of a force majeure clause

A properly drafted clause should identify the events that may qualify as force majeure and establish the consequences of their occurrence.

1. Definition of qualifying events: The clause should clearly identify events such as natural disasters, epidemics, government restrictions, and transportation interruptions.

2. Notice requirements: The affected party should notify the other party within the agreed period and provide relevant information about the disruption.

3. Mitigation obligations: The affected party should take reasonable steps to reduce the impact of the event and explore alternative supply arrangements.

4. Suspension of obligations: The clause should specify which contractual obligations may be temporarily suspended.

5. Payment obligations: It should clarify whether payment obligations for goods already delivered or services already performed remain enforceable.

6. Termination rights: The parties should establish when prolonged disruption allows either party to terminate the contract.

7. Quality and safety requirements: Any resumed supply must continue to satisfy applicable biotechnology product safety, storage, and regulatory requirements.

Important case laws

1. Satyabrata Ghose v. Mugneeram Bangur & Co. (1954)

The Supreme Court explained the scope of frustration under Section 56 of the Indian Contract Act. It held that impossibility does not necessarily mean literal physical impossibility; performance may also become impracticable or useless because of a fundamental change in circumstances.

The judgment is important for biotechnology supply contracts because extraordinary events may fundamentally affect the agreed commercial purpose or feasibility of performance.

2. Energy Watchdog v. Central Electricity Regulatory Commission (2017)

The Supreme Court clarified the distinction between force majeure under a contractual clause and frustration under Section 56. Where the contract contains an applicable force majeure provision, the matter is generally governed by Section 32 and the contractual terms.

This decision is particularly important when biotechnology manufacturers and suppliers negotiate detailed force majeure provisions.

3. Dhanrajamal Gobindram v. Shamji Kalidas & Co. (1961)

The Supreme Court examined the meaning and application of force majeure clauses. It recognised that the expression must be interpreted according to the language and intention of the contract.

The decision supports careful drafting of biotechnology supply agreements, particularly concerning epidemics, transportation disruptions, and government restrictions.

4. Alopi Parshad & Sons Ltd. v. Union of India (1960)

The Supreme Court held that commercial hardship or an increase in the cost of performance does not automatically discharge contractual obligations.

This principle is relevant when biotechnology suppliers face increased manufacturing costs, higher transportation expenses, or shortages of specialised raw materials.

5. Halliburton Offshore Services Inc. v. Vedanta Ltd. (2020)

The Delhi High Court considered the impact of the COVID-19 pandemic on contractual obligations and interim relief. The decision emphasised that the pandemic does not automatically excuse contractual non-performance; the actual contractual terms and circumstances must be examined.

Its reasoning is relevant to biotechnology supply chains disrupted by public health emergencies.

Challenges in biotechnology supply contracts

Force majeure disputes in biotechnology may involve difficulties in identifying the actual cause of disruption and determining whether alternative suppliers were reasonably available.

Other challenges include:

Shortages of specialised biological materials.

Loss of temperature-controlled storage facilities.

International export restrictions.

Expiry of sensitive biological products.

Disputes concerning delayed regulatory approvals.

Uncertainty regarding responsibility for additional costs.

A supplier cannot automatically rely on force majeure merely because performance has become more expensive or less profitable.

Recommendations

Biotechnology businesses should adopt the following contractual safeguards:

Draft specific force majeure definitions.

Include epidemics and government restrictions where appropriate.

Establish clear notification and evidence requirements.

Define reasonable mitigation obligations.

Provide alternative sourcing and supply-continuity arrangements.

Clarify payment and termination consequences.

Address temperature-sensitive product storage and transportation.

Establish dispute resolution and renegotiation procedures.

Conclusion

Force majeure clauses are essential for managing contractual uncertainty in biotechnology supply chains. They protect parties against qualifying extraordinary events while establishing procedures for maintaining supply continuity and allocating financial risks. Sections 32 and 56 of the Indian Contract Act, 1872, provide the principal legal framework. Judicial decisions such as Energy Watchdog, Satyabrata Ghose, and Dhanrajamal Gobindram explain the interpretation and application of force majeure principles. Carefully drafted contractual provisions can therefore reduce disputes and strengthen the reliability of biotechnology supply arrangements.

Legal clarification: Force majeure protection depends on the specific contractual wording and evidence of causation. The COVID-19 pandemic, increased costs, supply shortages, or regulatory delays do not automatically excuse non-performance under Indian law.